Clinical Trials
42
Active:7
Completed:16
Trial Phases
4 Phases
Phase 1:20
Phase 2:11
Phase 3:8
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
Phase 1
20 (47.6%)Phase 2
11 (26.2%)Phase 3
8 (19.0%)Not Applicable
3 (7.1%)Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Not Applicable
Recruiting
- Conditions
- Subjects With Mild Hypertension
- Interventions
- Drug: HRS-9563, placebo
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT07117474
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
Not Applicable
Not yet recruiting
- Conditions
- Hyperlipidemia
- Interventions
- Drug: HRS-7249 Injection
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07100418
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HRS953Drug: Placebo
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT07060456
- Locations
- 🇨🇳
Perking University Peoples' Hospital, Beijing, Beijing, China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Phase 3
Not yet recruiting
- Conditions
- Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06994650
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Phase 3
Not yet recruiting
- Conditions
- Bstructive Sleep Apnea (OSA) and Obesity
- Interventions
- Drug: HRS9531placebo
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06974851
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found